- KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
- 23 November 2015: Opening statement of Asia and the Pacific Group at Tenth Session of WIPO Advisory Committee on Enforcement
- US ITC notice for public comment, Jan 13, 2016 hearing, and Commission report on the TransPacific Partnership Agreement (TPP)
- My testimony this morning at the US ITC hearing on "Economic Impact of Trade Agreements"
- Seminars on Drug Pricing: Part 5 Kevin Outterson, Antibiotic Delinkage
- Tentative witness list for USITC hearing on Economic Impact of Trade Agreements
- Dr. Margaret Chan: TPP may "close access to affordable medicines"
- US Chamber of Commerce lauds USPTO for securing a time-bound LDC waiver for pharmaceutical products
- Economist Bhaven Sampat presents research on role of government funding in drug development
- Joint NGO Statement on TRIPS Council Decision On Extension of the Transition Period Concerning Pharmaceutical Products
After two days of intense negotiations over the future work program of WIPO's Standing Committee on the Law of Patents (SCP), the committee achieved consensus at around 3:40 PM Geneva time on Friday, 31 July 2015.
The future work of WIPO's main normative committee dealing with patents now has a pathway on the following work streams:
WIPO SCP22: Language on GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on InventionsSubmitted by thiru on 31. July 2015 - 1:55
On 30 July 2015 at 8:30 PM Geneva time, the Chair (Bucura Ionescu, Romania) of WIPO's 22nd Standing Committee on the Law of Patents (SCP) distributed the following non-paper related to the proposal by the Group of Latin American and Caribbean Countries (GRULAC) to revise the 1979 WIPO Model Law for Developing Countries on Inventions. If this language is tabled, WIPO's normative committee on patents will continue discussions on the GRULAC proposal.
SCP/22: PROPOSAL BY THE CHAIR
July 30, 2015
On 30 July 2015 at 8:30 PM Geneva time, the Chair (Bucura Ionescu, Romania) of WIPO's 22nd Standing Committee on the Law of Patents (SCP) distributed the following non-paper as a pathway for future work addressing 1) Exceptions and Limitations to Patent Rights, 2) Quality of Patents, Including Opposition Systems, 3) Patents and Health, 4) Confidentiality of Communications between clients and their patent advisors and 5) Transfer of technology. The SCP is WIPO"s main normative committee dealing with patents.
28 July 2015
WIPO Standing Committee on the Law of Patents (SCP)
Written Statement of Knowledge Ecology International on Patents and Health
As the Trans-Pacific Partnership (TPP) is currently reported to be in the final stages of negotiation, it is both appropriate and urgent that this Committee is addressing the topic of patents and health.
SCP22: Australian response to GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on InventionsSubmitted by thiru on 29. July 2015 - 9:59
On 29 July 2015, Australia provided the following response to the proposal by the Group of Latin American and Caribbean Countries (GRULAC) to revise the 1979 WIPO Model Law for Developing Countries on Inventions.
Australian Delegation Proposal
The Secretariat prepare a study on:
1) experiences of how developing countries and least developed countries (LDCs) have implemented the patent model law; or
2) to determine the unmet need for a patent model law.
Knowledge Ecology International (KEI) delivered the following intervention on 29 July 2015 during WIPO discussions on the proposal by the Group of Latin American and Caribbean Countries (GRULAC) to revise the 1979 WIPO Model Law for Developing Countries on Inventions.
KEI statement on GRULAC proposal (SCP/22/5)
WIPO Standing Committee on the Law of Patents (SCP)
29 July 2015
Proposal: Engage Member States in the Revision of the 1979 WIPO Model Law for Developing Countries on Inventions
India delivered this lengthy, nuanced intervention on inventive step on 28 July 2015 citing the US Supreme Court observations on a person skilled in the art (PSIA), the KSR Int'l Co. v. Teleflex, Inc. decision on obviousness as applied to patent claims, the IPAB Roche decision (in relation to inventive step) and jurisprudence from the House of Lords on inventive step.
India’s Intervention on a study on inventive step (SCP/22/3) at SCP/22
On Monday afternoon, 27 July 2015, Brazil on behalf of the Group of Latin American and Caribbean Countries (GRULAC) delivered the following opening statement which,inter alia, called for a
Attached is a letter from eleven of the 28 House Democrats that supported the Trade Promotion Authority (TPA) Fast Track legislation, on the topic of intellectual property rights and medicine. The letter, which is moderate and cautious in substance, but overall helpful given where negotiations stand, closes by telling Ambassador Froman that "As members who support trade done right, we strongly believe that TPP must not inhibit access to lifesaving medicines."
The World Intellectual Property Organization's (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) is taking place from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. The prior session of the Committee (November 2014) ended in deadlock. Ultimately, patents and health proved to be the deciding factor.
On Wednesday, July 22, 2015, the Senate Veterans Committee held a mark-up to consider several bills. During the mark-up, Senator Sanders offered an amendment, attached below, that would create a compulsory license mechanism in the Department of Veterans Affairs, for patents on medical inventions. (See amendment text below). The motivation for the amendment was a crisis in the VA involving access to drugs for the hepatitis C virus (HCV).
On the topic of the TPP and copyright, KEI has sent a letter to Maria Pallante, the Register of Copyrights, Shira Perlmutter, Chief Policy Officer and Director for International Affairs for USPTO, and Nancy Weiss, Senior Advisor to the Chief Technology Officer, Office of Science and Technology Policy (OSTP), Executive Office of the President.
KEI asked these agencies to address certain issues in the TPP intellectual property chapter that relate to access to copyright issues, with a focus on orphan works, and uses by governments.
On Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).